Intrust Bank NA Invests $383,000 in argenx SE (NASDAQ:ARGX)

Intrust Bank NA purchased a new stake in argenx SE (NASDAQ:ARGX) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 623 shares of the company’s stock, valued at approximately $383,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Whipplewood Advisors LLC acquired a new stake in argenx in the fourth quarter worth $37,000. Global Retirement Partners LLC raised its stake in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. Jones Financial Companies Lllp raised its stake in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after buying an additional 61 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in argenx by 78.6% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after acquiring an additional 33 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after acquiring an additional 21 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of ARGX opened at $589.15 on Monday. The company has a market cap of $35.80 billion, a PE ratio of -669.49 and a beta of 0.59. The firm has a 50-day moving average of $628.26 and a 200-day moving average of $602.12. argenx SE has a one year low of $352.77 and a one year high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Analyst Ratings Changes

ARGX has been the topic of several recent analyst reports. Piper Sandler lifted their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. Truist Financial reiterated a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Guggenheim raised their price objective on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, March 10th. JMP Securities upped their target price on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Finally, Robert W. Baird lifted their price target on argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.